- Home
- USIO vs PEPG Comparison
USIO vs PEPG Comparison
Compare USIO & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- PEPG
- Stock Information
- Founded
- USIO 1998
- PEPG 2018
- Country
- USIO United States
- PEPG United States
- Employees
- USIO N/A
- PEPG N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- PEPG Health Care
- Exchange
- USIO Nasdaq
- PEPG Nasdaq
- Market Cap
- USIO 50.2M
- PEPG 43.2M
- IPO Year
- USIO N/A
- PEPG 2022
- Fundamental
- Price
- USIO $1.52
- PEPG $1.29
- Analyst Decision
- USIO Strong Buy
- PEPG Buy
- Analyst Count
- USIO 1
- PEPG 3
- Target Price
- USIO $4.00
- PEPG $7.67
- AVG Volume (30 Days)
- USIO 104.3K
- PEPG 311.5K
- Earning Date
- USIO 08-06-2025
- PEPG 08-07-2025
- Dividend Yield
- USIO N/A
- PEPG N/A
- EPS Growth
- USIO N/A
- PEPG N/A
- EPS
- USIO 0.11
- PEPG N/A
- Revenue
- USIO $83,851,606.00
- PEPG N/A
- Revenue This Year
- USIO $16.02
- PEPG N/A
- Revenue Next Year
- USIO $13.24
- PEPG N/A
- P/E Ratio
- USIO $14.21
- PEPG N/A
- Revenue Growth
- USIO 2.05
- PEPG N/A
- 52 Week Low
- USIO $1.24
- PEPG $0.88
- 52 Week High
- USIO $2.92
- PEPG $10.15
- Technical
- Relative Strength Index (RSI)
- USIO 42.47
- PEPG 50.90
- Support Level
- USIO $1.38
- PEPG $1.37
- Resistance Level
- USIO $2.02
- PEPG $1.38
- Average True Range (ATR)
- USIO 0.13
- PEPG 0.13
- MACD
- USIO -0.03
- PEPG -0.01
- Stochastic Oscillator
- USIO 21.87
- PEPG 63.64
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.